Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial |
| |
| Authors: | Anca Prica Annette E. Hay Michael Crump Nicole Mittmann Lois E. Shepherd Ralph M. Meyer Kevin I. Imrie Nancy Risebrough Marina Djurfeldt Bingshu E. Chen Matthew C. Cheung |
| |
| Affiliation: | Canadian Cancer Trials Group, Queen’s University, Kingston, ON K7L 3N6, Canada; (A.E.H.); (M.C.); (N.M.); (L.E.S.); (R.M.M.); (K.I.I.); (N.R.); (M.D.); (B.E.C.); (M.C.C.) |
| |
| Abstract: | We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers. |
| |
| Keywords: | lymphoma autologous stem cell transplantation cost-effectiveness analysis |
|
